325 related articles for article (PubMed ID: 9563894)
1. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
2. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
4. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.
Davies B; Brown PD; East N; Crimmin MJ; Balkwill FR
Cancer Res; 1993 May; 53(9):2087-91. PubMed ID: 8347186
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice.
Wang X; Fu X; Brown PD; Crimmin MJ; Hoffman RM
Cancer Res; 1994 Sep; 54(17):4726-8. PubMed ID: 8062271
[TBL] [Abstract][Full Text] [Related]
6. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
7. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
8. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
Eccles SA; Box GM; Court WJ; Bone EA; Thomas W; Brown PD
Cancer Res; 1996 Jun; 56(12):2815-22. PubMed ID: 8665519
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models.
Watson SA; Morris TM; Robinson G; Crimmin MJ; Brown PD; Hardcastle JD
Cancer Res; 1995 Aug; 55(16):3629-33. PubMed ID: 7627972
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Belotti D; Paganoni P; Manenti L; Garofalo A; Marchini S; Taraboletti G; Giavazzi R
Cancer Res; 2003 Sep; 63(17):5224-9. PubMed ID: 14500349
[TBL] [Abstract][Full Text] [Related]
11. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
Dabrowska A; Giermasz A; Marczak M; Gołab J; Jakóbisiak M
Anticancer Res; 2000; 20(1A):391-4. PubMed ID: 10769685
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
13. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect.
Silver DF; Piver MS
Gynecol Oncol; 1999 May; 73(2):280-4. PubMed ID: 10329047
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antineoplastic effects of cisplatin by a calmodulin antagonist (W-7) in nude mice bearing human ovarian carcinoma.
Oomori K; Kikuchi Y; Kita T; Iwano I; Kizawa I; Kato K
Cancer Detect Prev; 1988; 12(1-6):481-6. PubMed ID: 3180142
[TBL] [Abstract][Full Text] [Related]
15. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
16. Malignant behavior and resistance to cisplatin of human ovarian carcinoma xenografts established from the same patient at different stages of the disease.
Masazza G; Lucchini V; Tomasoni A; Peccatori F; Lampasona V; Giudici G; Mangioni C; Biondi A; Giavazzi R
Cancer Res; 1991 Dec; 51(23 Pt 1):6358-62. PubMed ID: 1933898
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
18. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
Schiller JH; Bittner G
Clin Cancer Res; 1999 Dec; 5(12):4287-94. PubMed ID: 10632372
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat.
Corbel M; Caulet-Maugendre S; Germain N; Molet S; Lagente V; Boichot E
J Pathol; 2001 Apr; 193(4):538-45. PubMed ID: 11276015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
